Selenium treatment in thyreopathies
Authors:
Štefan Sotak
Authors‘ workplace:
I. interná klinika LF UPJŠ a UN L. Pasteura Košice, Slovenská republika
Published in:
Vnitř Lék 2017; 63(12): 949-951
Category:
Reviews
Overview
Selenium (latin Selenium) is a micronutrient embedded in several proteins. In adults, the thyroid is the organ with the highest amount of selenium per gram of tissue. Selenium levels in the body depend on the characteristics of the population and its diet and geographic area. In the thyroid, selenium is required for the antioxidant function and for the metabolism of thyroid hormones. The literature suggests that selenium supplementation of patients with Hashimoto’s thyroiditis is associated with a reduction in antithyroperoxidase antibody levels. Selenium supplementation also in mild Graves’ orbitopathy is associated with delayed progression of ocular disorders. As a consequence of this observation The European Group on Graves’ Orbitopathy recommend six months selenium preparates supportive therapy for patients with mild form of Graves’ orbitopathy.
Key words:
Graves-Basedow’s disease – Hashimoto’s thyroiditis – selenium – supplementation
Sources
1. Duntas LH, Benvenga S Selenium: an element for life. Endocrine 2015; 48(3): 756–775. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–014–0477–6>.
2. Rayman MP. Selenium and human health. Lancet 2012; 379(9822): 1256–1268. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(11)61452–9>.
3. Park K, Rimm E, Siscovick D et al. Demographic and lifestyle factors and selenium levels in men and women in the U.S. Nutr Res Pract 2011; 5(4): 357–364. Dostupné z DOI: <http://dx.doi.org/10.4162/nrp.2011.5.4.357>.
4. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds; N. A. P. (US) Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington (DC), USA: 2000. Vitamin C, Vitamin E, Selenium, and β-Carotene and Other Carotenoids: Overview, Antioxidant Definition, and Relationship to Chronic Disease. In: Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds.- National Academies Press (US): Washington (DC) 2000. ISBN 0–309–06949–1. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/books/NBK225471/>.
5. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicologic Profile for Selenium. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service 2003. Dostupné z WWW: <https://www.atsdr.cdc.gov>.
6. MacFarquhar JK, Broussard DL, Melstrom P et al. Acute selenium toxicity associated with a dietary supplement. Arch Int Med. 2010; 170(3): 256–261. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2009.495>.
7. Kvíčala J. Zvýšení příjmu mikronutrientu selenu – utopie, fikce, prozřetelnost či nutnost? II. část. Interní Med 2003; 5(7): 354–359.
8. Ventura M, Melo M, Carillho F. Selenium and Thyroid Disease: From Patophysiology to Treatment. Int J Endocrinol 2017; 2017: 1297658. Dostupné z DOI: <http://dx.doi.org/10.1155/2017/1297658>.
9. Gartner R, Gasnier BC, Dietrich JW et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 2002; 87(4): 1687–1691.
10. Turker O, Kumanlioglu K, Karapolat I et al. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 2006; 190(1): 151–156.
11. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors 2003; 19(3–4): 165–170.
12. Nacamulli D, Mian C, Petricca D et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol 2010; 73(4): 535–539. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2009.03758.x>.
13. Mao J, Pop VJ, Bath SC et al. Effect of low-dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild-to-moderate iodine deficiency. Eur J Nutr 2016; 55(1): 55–61. Dostupné z DOI: <http://dx.doi.org/10.1007/s00394–014–0822–9>.
14. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 2003; 148(4): 389–393.
15. Rasmussen LB, Schomburg L, Kohrle J et al. Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol 2011; 164(4): 585–590. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-10–1026>.
16. Derumeaux H, Valeix P, Castetbon K et al. Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults. Eur J of Endocrinol 2003; 148(3): 309–315.
17. Wu Q, Rayman MP, Lv H et al. Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 2015; 100(11): 4037–4047. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–2222>.
18. Wertenbruch T, Willenberg HS, Sagert C et al. Serum selenium levels in patients with remission and relapse of Graves’ disease. Med Chem 2007; 3(3): 281–284.
19. Bülow Pedersen I, Knudsen N, Carle A et al. Serum selenium is low in newly diagnosed Graves’ disease: a population-based study. Clin Endocrinol (Oxf) 2013; 79(4): 584–590. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12185>.
20. Vrca VB, Skreb F, Cepelak I et al. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004; 341(1–2): 55–63.
21. Wang L, Wang B, Chen SR et al. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease: a prospective pilot study. Horm Metab Res 2016; 48(9): 559–564. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0042–110491>.
22. Bahn RS. Graves’ ophthalmopathy. N Eng J of Med 2010; 362(8): 726–738. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0905750>.
23. Dehina N, Hofmann PJ, Behrends T et al. Lack of Association between Selenium Status and Disease Severity and Activity in Patients with Graves’ Ophtalmopathy. Eur Thyroid J 2016; 5(1): 57–64. Dostupné z DOI: <http://dx.doi.org/10.1159/000442440>.
24. Khong JJ, Goldstein RF, Sanders KM et al. Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study. Clin Endocrinol (Oxf) 2014; 80(6): 905–910. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12392>.
25. Marcocci C, Kahaly GJ, Krassas GE et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364(20): 1920–1931. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1012985>.
26. Bartalena L, Baldeschi L, Boboridis K et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5(1): 9–26. Dostupné z DOI: <http://dx.doi.org/.10.1159/000443828>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 12
Most read in this issue
- The current role of warfarin
- Citalopram and QT prolongation
- Drug induced tendon injury
- Unusual history of Wilson disease: a case report and review of the literature